Sign In
Buy JNJ
$241.00
+1.92 (+0.80%)
At Close: Jun 24, 2026
J&J (JNJ) Seeks Approval for Bladder Cancer Drug in Europe
01:32pm, Monday, 11'th Sep 2023
J&J's (JNJ) erdafitinib is already marketed as Balversa in the United States for FGFR-altered metastatic UC. Balversa is approved by the FDA under the accelerated pathway.
AstraZeneca's Tagrisso-chemo combo results raise bar for J&J cancer drug-analysts
08:15am, Monday, 11'th Sep 2023
Data released on Monday by AstraZeneca from a late-stage trial combining its blockbuster cancer drug Tagrisso with chemotherapy to treat a type of lung cancer raises the bar for Johnson & Johnson's ri
Could This Issue Sink Johnson & Johnson's Stock Price?
06:49am, Monday, 11'th Sep 2023
Three of Johnson & Johnson's drugs could generate less revenue due to the Inflation Reduction Act. However, these three products are no longer part of Johnson & Johnson's long-term growth plans anyway
3 Bulletproof Stocks to Buy Before the Next Recession Strikes
06:27am, Monday, 11'th Sep 2023
With ongoing uncertainties in the stock market, investors' search for bulletproof stocks becomes paramount. Investors seek refuge in stable and growth-oriented stocks as the specter of economic downtu
The 7 Best Warren Buffett Stocks to Buy Now: September 2023
01:54pm, Sunday, 10'th Sep 2023
If we're going to get right down to it, banking on the best Warren Buffett stocks comes down to leveraging decades of experience. Unlike, say, financial luminaries on YouTube, the Oracle of Omaha has
The 5 Best Healthcare Stocks to Buy Now: September 2023
07:13pm, Friday, 08'th Sep 2023
In today's dynamic market, many investors are paying attention to the healthcare sector. The segment is known for its resilience and potential for growth.
September Rally? 3 Healthcare Stocks to Buy Before Liftoff.
11:56am, Friday, 08'th Sep 2023
With inflation taking center stage once again, it's becoming clear that consumers are prioritizing wants and needs. One of those “non-discretionary” expenses is healthcare, which makes it a good t
7 Best Blue Chip Stocks to Buy Now
09:46am, Friday, 08'th Sep 2023
Sure, short-term gains from the hip "stock of the moment" can be an exciting roller coaster ride, but if you're a truly savvy investor in 2023, you're going to be hunting for stocks that can provide s
3 Shaky Stocks to Sell in September Before It's Too Late
06:17am, Friday, 08'th Sep 2023
Investing in companies you know and understand is the best advice I learned when I started to invest. Familiarity with due diligence made the stock-picking process faster and more manageable.
The 7 Best Dow Stocks to Buy Now: September 2023
06:00am, Friday, 08'th Sep 2023
Finding the best Dow stocks to buy can be complex. The companies listed in the Dow Jones Industrial Average tend to be blue-chip stocks that have large market capitalizations and are dominant in their
3 Stocks Awaiting Winter Winds of Opportunity
10:45am, Thursday, 07'th Sep 2023
As we bid farewell to the sun-soaked days of summer, heralded by the Labor Day long weekend, and prepare to embrace the impending chill of winter, a curious phenomenon unfolds in the world of stocks.
J&J Spinoff Kenvue is the New Dividend Aristocrat on the Block
09:59am, Thursday, 07'th Sep 2023
You're familiar with its products, including Tylenol, Neutrogena, Listerine and Johnson's Baby Shampoo. Still, you may not be up to speed on Kenvue Inc. NYSE: KVUE and its status as a long-term divide
J&J (JNJ) to End Pulmonary Hypertension Study on Opsumit
09:46am, Thursday, 07'th Sep 2023
The decision to end the CTEPH study on J&J's (JNJ) Opsumit (macitentan) was made at the recommendation of the study's independent DMC, following a pre-planned interim analysis.
1 Brand-New Dividend Stock Income Investors Won't Want to Miss
09:05am, Thursday, 07'th Sep 2023
Kenvue, which was recently spun off from Johnson & Johnson, already pays an attractive dividend. The company supports that payout with a strong financial profile and durable business.
J&J to pull the plug on hypertension drug study
06:01pm, Wednesday, 06'th Sep 2023
Johnson & Johnson said on Wednesday it has decided to stop a late-stage study testing its experimental drug to treat a type of hypertension.
